General Information of Drug (ID: DMMAE3C)

Drug Name
PMID27998201-Compound-2 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Patented [1]
Cross-matching ID
TTD Drug ID
DMMAE3C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Drug(s) Targeting Cathepsin B (CTSB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [1]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [1]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [1]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [1]
PMID27998201-Compound-11 DMTV5NU Metastatic cancer 2D50-2E2Z Patented [1]
PMID27998201-Compound-22 DMS9QA7 Alzheimer disease 8A20 Patented [1]
PMID27998201-Compound-13 DMZHIM8 Hepatic fibrosis DB93.0 Patented [1]
Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 DMZ4B3W Cerebral ischemia 8B11 Patented [1]
PMID27998201-Compound-24 DM25BNZ Glioma 2A00.0 Patented [1]
L-006235-1 DMMEH12 Osteoarthritis FA00-FA05 Preclinical [2]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin B (CTSB) TTF2LRI CATB_HUMAN Inhibitor [1]

References

1 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
2 Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.